smmt takeaway ridinilazol track discuva
look direct recent sell-off
put gvhd perspect
post-approv strategi outlin investor day reiter
put take cvr move rate outperform
preview expect season soft focu sale forc
intrigu updat lgmd question remain
takeaway gvhd expert call
novemb ghdx vote like result upward revis
note analyst day posit clinic updat includ
analyst certif import disclosur see
quietli make progress ahead major updat
top stori week administr announc anoth plan would use healthcar coverag way reduc
immigr establish rule would limit visa approv financi burden countri
healthcar system peopl would need prove accept health insur would abl gain coverag
smmt takeaway ridinilazol track discuva germin
summit therapeut smmt host day slide present event includ
high unmet need difficil infect cdi exhibit could fundament address ridinilazol
commerci launch ridinilazol cdi could potenti better expect early-stag discuva platform
could piqu investor interest next month new project enter clinic expect acceler newsflow
ridininilazol phase trial next quarter updat commerci prep ahead potenti approv
critic success launch stay neutral smmt evolv view execut differenti
approach antibiot develop savvi new investor on-board
look direct recent sell-off
given share continu weaken follow leg heel compani investor day
sinc close vs nbi period field stream call investor seek interpret
given lack obviou fundament disappoint better inform view hold one-hour teleconfer
two academ urologist next monday et discuss updat registr data urotheli
carcinoma well earli phase data non-muscl invas bladder cancer present
event also discuss aspect contempl commerci prospect well
remain develop need secur nmibc approv also take opportun cover emerg
therapeut cancer treat urologist compani within univers ancn veru well other
put gvhd perspect
given read-out expect investor focus gvhd opportun
report attempt put studi potenti result perspect background oppenheim
mark breidenbach host expert call dr joseph antin professor medicin harvard medic school chief
emeritu stem cell transplant program depart medic oncolog dana-farb cancer institut
key topic discuss studi gvhd itacitinib ruxolitinib corticosteroid current
treatment chronic acut gvhd dr antin interest random trial compar
experiment agent steroid vs placebo steroid real soc gvhd detail insid
given phase catalyst rimegep troriluzol believ continu two-fer opportun
launch almost year ago investor focu remain rimegep howev offer multipl valu
driver reflect current trade level note attempt frame catalyst potenti upside/
downsid scenario specif address rimegep phase top-line prevent episod migrain patient
troriluzol phase data gener anxieti disord gad remain optimist rimegep read-out statist
signific primari endpoint preliminari address market opportun estim troriluzol gad
also note gad data could read-through psychiatr indic especi ocd
post-approv strategi outlin investor day reiter outperform
tuesday host investor event new york highlight voxelotor could reshap treatment paradigm
sickl cell anemia sca event includ testimoni kol patient advoc high physic econom
burden associ sca emphas import address hemolyt anemia compon diseas
manag overview prepar commerci launchwith sale forc alreadi board
intend caught off-guard voxelotor approv ahead februari pdufa date manag overview plan
multipl confirmatori trial start trial pediatr patient elev risk stroke
believ well-pois success transit commerci stage reiter outperform pt
put take cvr move rate outperform
follow sobi offer acquir dova move rate outperform rescind pt provid
thought deal cvr attract investor attent sinc initi ascrib
fundament valu believ current deal unlock strateg basi due cvr non-transfer
natur receiv investor interest program likelihood success ultim pay-out deal conting
approv doptelet cvr stipul payment whose present risk-adjust valu peg
furthermor provid addit thought dova/sobi deal timelin toward deal consumm
expect complet come month
preview expect season soft focu sale forc expans
would buyer prior updat expect earli novemb base expect investor
primarili focus potenti updat sale forc expans in-lin quarter revis revenu
estim consensu potenti rais least bottom end rang current
revenu guidanc estim believ sale forc expans potenti around
rep posit healthi growth addit expect updat potenti barda procur
nexobrid next six month forecast call barda contribut revenu believ
could upsid outlook
intrigu updat lgmd question remain
sarepta report updat nine-month function data three patient lgmd phase clinic protocol
compani acquir start-up myonexu updat low-dos arm patient
februari call function improv slide three patient intriguingand felt
question still remain compani chang origin lgmd protocol patient six
high dose three placebo compar natur histori might appropri slide sprt
indic on-studi lgmd patient mild compani execut commerci manufactur
takeaway gvhd expert call
monday host confer call graft vs host diseas gvhd dr joseph antin expert hematopoiet
transplant dana farber cancer institut gvhd common potenti seriou complic allogen stem cell
transplant despit recent advanc option avail patient fail frontlin prednison dr antin emphas
import blind placebo-control trial gvhd highli vulner bias respons assess
nonetheless express optim non-immunosuppress target therapi includ jak inhibitor
despit recent approv ibrutinib chronic gvhd ruxolitinib acut gvhd
dr antin see high unmet need patient high-grad gvhd would welcom new addit treatment
armamentarium overal believ dr antin view favor toward develop includ
kymab less favor toward blcm kd mlm meso
last week presid trump issu execut order strengthen medicar provid save senior
encourag supplement benefit reduc provid burden acceler technolog adopt reduc fraud wast
abus meanwhil hospit payer said post price help price transpar would
confus patient question legal mhn final rise provid frustrat prior author
paperwork open door technolog emr autom cumbersom manual process mhn
novemb ghdx vote like result upward revis guidanc
genom health set novemb sharehold vote merger roughli month earlier
previous expect see materi gate factor complet transact believ deal may close
mid-novemb like upsid revenu estim assum genom revenu
contribut like reset manag guidanc around financi result confer call reflect
merger contribut earlier expect close support invest thesi call merger synergi
exceed manag target year three deliv acceler timelin posit cash flow
oper potenti begin
under-perform broader biotech sector past two year vs nbi index
ytd vs nbi index signific portion driven investor fear regard robust
commerci treprostinil franchis opco/consensu expect q/q declin due gener remodulin entri
delay launch implant system remodulin isr key bulwark iv remodulin gener
pauciti identifi catalyst need re-rat stock think concern could allevi next
month mani busi fundament execut come fruition stay bullish
note analyst day posit clinic updat includ
analyst day report increment clinic data lead candid r/r follicular lymphoma
pivot ph trial on-going r/r small/chron lymphocyt leukemia sll/cll believ continu illustr
best-in-class potenti importantli evid substanti hypothesi intermitt dose
significantli mitig advers event risk associ inhibitor nonetheless gener meaning durabl
tumor respons believ grow investor recognit commerci prospect drive stock out-performance
catabasi catb present find slide phase movedmd trial open-
label extens edasalonex intern annual congress world muscl societi present
reiter nf-b role dmd key factor diseas progress skelet cardiac muscl inhibit nf-b
target gene set peripher blood treatment edasalonex substanti slow dmd diseas progress
demonstr inflamm biomark serum c-reactiv protein muscl mri function endpoint nsaa
data strongli support on-going phase polarisdmd studi bullish view
septemb bway announc yaacov michlin resign ceo pursu busi opportun
believ drive forc michlin part way bway board desir increas manag us presenc
remind late august bway announc cfo hadar levi would reloc us israel take
role well bway board intend appoint us-bas ceo mr michlin successor bway co-found
chairman board dr david zacut serv interim ceo near-term disrupt risk manag
transit continu focu compani build opportun includ ocd smoking-cess ptsd data
latter two expect year-end
quietli make progress ahead major updat
make progress ahead import readout lead asset mf decemb
expect data substanti number patient combin arm well arm data catalyz
registr discuss fda current plan baselin assumpt mf requir acceler
approv may base spleen volum reduct svr symptom improv tss acceler
approv could base td ti convers meanwhil progress made privat placement
remov financ overhang cash last also dose first patient
inhibitor solid tumor
oct physician expert call emerg therapi urolog oncolog
oct houston oncolog summit md anderson cancer center
expert call wilson diseas treatment landscap opportun
healthcar provid manag
